Xenetic Biosciences Inc (XBIO) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access XBIO Annual Balance Sheets →
Quarterly balance sheet trends provide context on Xenetic Biosciences Inc's liquidity, leverage, and long-term financial structure.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent7.35
Cash & Short-term Investments7.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.25
Total Current Assets7.60
Other Assets, Noncurrent0.31
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Total Assets7.91
Liabilities
Accounts Payable, Current AC0.56
Other Liabilities, Current0.40
Total Current Liabilities0.96
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Total Liabilities0.96
Stockholders' Equity
Treasury Stock Common Value-5.28
Common Stock Value0.00
Additional Paid In Capital Common Stock212.31
Retained Earnings / Accumulated Deficit-200.33
Other Equity0.25
Common Stockholder's Equity6.95
Preferred Stockholder's Equity0.00
Total Stockholder's Equity6.95
Liabilities & Stockholder's Equity7.91
4 historic quarters locked

Sign in to unlock the full Xenetic Biosciences Inc balance sheet history.

About Xenetic Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001683168-26-006061

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.